CD19 and metastatic neoplasm: Together, these results indicate that CD19+ B cells primed in the 67NR tumor context acquire regulatory functions capable of counteracting pro-osteoclastogenic signals mediated by metastatic tumor-specific CD3+ T cells previously shown to be RANKL-dependent through OPG production (25).